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1. ABSTRACT 
The OECD test guideline 428 for the assessment of dermal absorption in vitro has 
been in force for more than a decade. Various sectors of industry utilise the method for the 
registration of chemical products. These include the Agrochemical and Cosmetic sectors 
where the OECD test guideline and industry-specific guidance forms a key part of the 
human risk assessment process for new and existing products.  This investigation has 
compared the dermal absorption characteristics of one of the OECD 428 reference 
chemicals, testosterone, in human and pig dermatomed skin. We used identical dosing 
and skin decontamination conditions for testosterone in Franz static diffusion cells. This 
included a full mass balance recovery of the dose applied and distribution of the 
compound in the different layers of the skin. Our investigation has shown that intact human 
skin provides a more effective barrier to the dermal absorption of testosterone compared 
with pig skin, when studied according to modern day in vitro dermal absorption guidance.  
 
Keywords:  Dermal Absorption; Dermatomed skin; Electrical Resistance (ER); OECD 
428; Tape stripping; In vitro percutaneous absorption 
 
2. INTRODUCTION 
The assessment of the dermal absorption potential of active ingredients in cosmetic, 
agrochemical and industrial chemical products that come into contact with the skin is a key 
part of human risk assessment.  This ensures that under normal, or expected conditions, 
based on the hazard potential of a particular chemical, there is a sufficient margin of safety 
for manufacturers, handlers and end users of products who may be exposed to products 
containing the active chemical.  The assessment of dermal absorption for human risk 
assessment follow the OECD 428 test guideline which almost exclusively involves in vitro 
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techniques that utilises donated human or animal skin. There are now very few dermal 
absorption studies undertaken in vivo, since in vitro studies using resected skin have been 
shown to be predictive of man for a variety of chemicals across multiple industrial sectors 
(WHO, 2006). The OECD 428 approach is now used extensively, particularly by the 
personal care/cosmetic and agrochemical industries, and forms a key part of the human 
risk assessment and registration process for new and existing chemicals that come into 
contact with the skin either intentionally or during their occupational use. 
The OECD 428 test guideline has been used for many years as a stand-alone in vitro 
method for predicting dermal absorption (OECD, 2004a) and this has led to a major 
reduction in animal use in this area of toxicology and new product development. Current 
regulations for the registration of consumer products and agrochemicals in the European 
Union use industry-specific protocols for dermal penetration that are aligned to the 
methods described in OECD 428. For example, the Scientific Committee on Consumer 
Safety for cosmetic ingredients (SCCS, 2010) and European Food Safety Authority for 
pesticide-containing products (EFSA, 2012) have their own additional dermal absorption 
guidance for cosmetic and agrochemical products, respectively.  
Each of these industry-specific guidance documents permits the use of alternative 
species to human skin. In the case of agrochemicals, rat skin is sometimes used, not 
because it is recognised as a good model for man, far from it, but in order to bridge 
between historical or contemporary data that has been generated on the product in the rat 
in vivo (EFSA, 2012). In the case of personal care and cosmetic products where animal 
studies are not used, the SCCS guidance (SCCS, 2010) also permits the use of pig skin in 
vitro, in addition, to the more conventional human skin models. The pig is regarded as 
being a reasonable surrogate for human skin with regard to skin permeability 
characteristics and morphology (Benech-Kieffer et al, 2000; Gerstel et al, 2016; Dick and 
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Scott, 1992; WHO, 2006). Pig skin is also used for formulation development and product 
selection by the pharmaceutical industry ahead of the more costly human studies 
(Herkenne et al, 2016). It was therefore of interest to compare human and pig skin side-by-
side in an identical OECD 428 protocol, based largely on the EFSA Guidance 
recommendations, which include an interim decontamination step and full mass balance 
recovery of the chemical in question, 24 hours following skin exposure.  
Testosterone was selected as the representative chemical for this comparative study 
since it is one of the reference chemicals recommended in the OECD test guideline 428 to 
be tested periodically to demonstrate the performance of the method, particularly in 
laboratories that are less familiar with the in vitro method (OECD, 2004a).  Furthermore 
testosterone has been widely studied over many years in human in vitro and in vivo 
models (Bronaugh and Franz, 1986) and as a therapeutic agent for a variety of medical 
purposes (Hadgraft and Lane, 2015). Although, our own laboratory (Heylings et al., 2007) 
and others (van de Sandt et al, 2004) have compared the dermal penetration properties of 
testosterone and other standard reference chemicals in different species in previous multi-
laboratory investigations, a new up-to-date evaluation of the OECD 428 approach using 
dermatomed skin and other methodological aspects that have been introduced over the 
years, may prove useful for others involved with these types of studies.  
Regulatory studies of in vitro dermal absorption undertaken in the 1990s and early 
2000s often involved the use of heat-separated epidermal membranes (ECETOC 1993, 
ECVAM 1996). However, industry guidance now recommends the use of split-thickness 
skin, which is prepared with a dermatome (EFSA 2012; SCCS, 2010). This produces skin 
preparations that have not only the stratum corneum barrier and underlying epidermis, but 
a thin layer of dermis beneath that is in contact with the receptor fluid. In these modern day 
studies, the “absorbed dose”, or that which is regarded as systemically available, includes 
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the test chemical remaining in the skin, following tape stripping, and is not assessed by 
flux alone, which only measures the test chemical in the receptor fluid over a time course. 
Consequently, dermatomed skin that forms the basis for this investigation has become the 
main skin preparation technique for regulatory studies and use of a finite (low volume) 
application of the product containing the test chemical (Heylings, 2015). 
 
3. METHODS 
3.1 Preparation of dermatomed skin membranes 
Human skin used for this investigation was approved by the NHS Local Research 
Ethics Committee and donated tissue was supplied by The National Disease Research 
Interchange (NDRI), Philadelphia, USA. We use a strict protocol for the sourcing of human 
tissue. We utilise the abdominal region for these studies since the skin permeability, 
thickness of the stratum corneum as well as follicle density and depth have intermediate 
properties, compared with other regions of the human body. In addition it is important that 
the skin is not swabbed with any chemicals such as iodine or ethanol prior to freezing.  
Since an important aspect of any human investigation is the inter-subject response, skin 
samples from at least 4 different human donors were used. Care was taken not to use any 
area of the skin that appeared abnormal or where the sample had been folded prior to 
freezing. Pig skin preparations used for this investigation were from animals of the British 
White strain of pig (aged 6-8 weeks) that had been bred for food and were sourced from a 
local abattoir. The flank region of the animal was used in these investigations. As part of 
the experimental design we ensured that at least 4 different animals were used in the dose 
group. Skin membranes (approximately 6 cm diameter) from both species were cut at a 
thickness of 400 µm using an electric dermatome. The edges of the skin sample were 
avoided to ensure uniform thickness of each specimen. Each skin membrane was given a 
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unique identifying number and stored frozen, at -20oC, on aluminium foil, until required for 
use. 
 
3.2 In vitro static diffusion cell equipment and measurement of skin integrity 
Details of the diffusion cell assembly used in these investigations are described in the 
OECD Guideline 428 (OECD, 2004a) and Guidance Document No. 28 (OECD, 2004b). 
The test guideline shows a diagram of our modified glass static diffusion cell, based on the 
original design of this device (Franz, 1975). Other publications from our laboratory 
describe the type of glass static diffusion cells in more detail (Scott and Clowes, 1992), 
and the mass balance procedure used to define systemic exposure in modern day studies 
(Heylings, 2014). Our automated static diffusion cell system is depicted pictorially in more 
recent publications (Heylings, 2015a).  
Discs of dermatomed human or pig skin approximately 3.3 cm diameter were 
mounted dermal side down.  Each cell had an exposed area of skin of 2.54 cm2.  The 
receptor chambers were filled with a recorded volume of physiological saline, containing 
5% bovine serum albumin and 0.1% sodium azide.  The preparations were placed on a 
magnetic stirrer plate and semi-immersed in a water bath maintained at a skin temperature 
of 32 ± 1oC.  Prior to use, the skin integrity of each membrane was assessed to ensure 
that each skin sample had not been damaged during procurement, shipping, storage or 
during the dermatoming procedure. It should be stressed that the assessment of skin 
integrity is probably the most important aspect of the whole in vitro dermal absorption 
method. Not only is it an OECD guideline requirement, but laboratories need to ensure that 
they are applying test compounds to skin with an intact barrier. In this investigation, skin 
integrity assessment was undertaken by measuring the Electrical Resistance (ER) of each 
sample in the diffusion cell and the acceptance/rejection criteria established previously for 
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normal intact skin in our laboratory for different species (Heylings et al., 2001; Davies et 
al., 2004) in our static diffusion cells. Resistance across each membrane was measured 
using a PRISM Electronics AIM6401 LCR data bridge and was expressed as k/cell area. 
This method measures the resistance (or impedance) of skin samples in diffusion 
chambers and has been shown by several laboratories to be representative of skin barrier 
function (Lawrence et al., 1997; Davies et al., 2004; WHO, 2006; Heylings, 2012).  The 
glass diffusion chambers containing human or pig skin were allowed to equilibrate in a 
water bath at 32oC for approximately 30 minutes. Following this, one electrode was 
inserted into 4.5ml of saline via the receptor chamber side arm and another electrode was 
placed into 2ml of saline pipetted into the donor chamber.  Once stabilised, the resistance 
value for each skin sample was recorded. The saline in the donor chamber was then 
removed and the skin allowed to dry naturally. Previous studies in our laboratory had 
established the ER values for intact skin from different species and different methods of 
skin preparation. These cut-off values for intact skin were established in our 2.54cm2 
surface area Franz static diffusion cells as used in this investigation (Davies et al., 2004). 
Any human skin membranes that had an ER value below 10 k or below 3 k for pig skin 
were regarded as having poor skin integrity for that particular species and were not used in 
these investigations.  
 
3.3 Application of Testosterone 
 Unlabelled testosterone was obtained from Sigma-Aldrich (The Old Brickyard, New 
Road Gillingham, Dorset. UK) and [4-14C]-testosterone was obtained from Quotient 
Bioresearch (Radiochemicals) Ltd, Cardiff, UK.  The receptor chambers of the cells were 
filled with a recorded volume of 0.9% aqueous NaCl + 5% bovine serum albumin + 0.01% 
sodium azide. A mixture of unlabelled and [14C]-testosterone was dissolved in 40% ethanol 
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in water to make a 1mg/ml dosing solution with a radioactivity content of approximately 
2 MBq/mL.  The purity and testosterone concentration of the dose preparations (40% 
ethanol : 60% water w/w) was confirmed by HPLC and radiochemical detection by LSC. A 
finite skin application rate of 10 µL/cm2 was used, equivalent to a dose of 10 µg 
testosterone/cm2. This was applied to the surface of the skin membranes. In the case of 
human skin we dosed four pairs human donor skin in order to be able to investigate any 
inter-subject differences in response. The glass diffusion cells were placed semi-immersed 
in a water bath maintained at 32oC ± 1oC. The receptor fluid beneath the skin was 
constantly mixed with a magnetic stirrer so the auto-sampler collection of a small volume 
could be used to calculate the amount of testosterone that had penetrated into the 
receptor fluid at any given time point. 
 Samples (0.5 mL) of the receptor fluid were taken manually immediately before 
dosing and then at 1, 2, 3, 4, 5, 6, 7 and 8 h, using an auto-sampler. The volume of fluid in 
the receptor chamber was maintained by the replacement of a volume of receptor fluid, 
equal to the sample volume immediately after each sample was taken.  At the scheduled 
interim washing time of 8 h, a mild skin washing procedure was performed which involved 
the swabbing of the skin surface firstly with sponges pre-wetted with a dilute soap solution 
and then sponges pre-wetted with water. Finally, the skin surface was rinsed with a single 
aliquot of water before returning the cells to the water-bath.  Further samples of receptor 
fluid were collected at 10, 12, 14, 16, 18, 20, 22 and 24 h after application and analysed 
for testosterone.  At 24 h, the donor chamber was carefully detached from the cell 
assembly and the terminal skin washing procedure and mass balance was performed. The 
skin washing regime involved the same sponge and water wash described previously after 
which the skin was allowed to dry naturally prior to removal of the stratum corneum by 
tape stripping. The skin stripping method followed the standard approach described in test 
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guideline OECD 428 (Trebilcock et al., 1994), using repeated application of adhesive tape 
(Scotch 3M Magic Tape, 1.9 cm wide).  A maximum of 15 individual tape strips were taken 
from each skin sample and the testosterone content in each strip was measured by LSC, 
following extraction from the tape. 
The flange skin (the unexposed/undosed skin which had been held between the 
donor and receptor chamber) was cut away and the epidermis was separated from the 
dermis by heat separation.  Each sample of epidermis and dermis was separately 
solubilised with tissue digestant prior to analysis for testosterone by LSC, following the 
addition of scintillation fluid.  Likewise, the radioactivity content of each of the receptor fluid 
samples was also determined at each time point.  
 
3.4 Calculations and statistical analyses 
 The time-course absorption of testosterone into the receptor fluid was calculated by 
dividing the amount of test penetrant at each time point by the area of exposed 
dermatomed skin (2.54 cm2) and plotting the results as amount of testosterone absorbed 
(µg/cm2) versus time (h). The slope of the absorption profile between given time points 
provided the rate of absorption of testosterone per cm2 of the skin (µg/cm2/h) during that 
period. The proportion (µg/cm2) of testosterone that was recovered from the individual 
compartments of the system (donor chamber, skin wash, tape strips, flange, epidermis, 
dermis and receptor fluid) was expressed as a percentage of the actual amount applied to 
the surface of each skin membrane. This allowed a full mass balance distribution of 
testosterone to be determined in accordance with the OECD 428 test guideline.  The 
human and pig skin values were expressed as mean ± SD for each compartment.  A 
comparison was made between the dermal absorption observed in each species using 
Student’s t-test for unpaired variates. 
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4. RESULTS 
4.1 Skin Penetration of Testosterone through Human Dermatomed Skin 
The dermal absorption of testosterone through human skin into the receptor fluid 
gave a typical exponential type time course profile (Figure 1). After a lag phase of about 1 
hour there was a relatively fast phase of absorption. The interim wash at 8h, which is part 
of the EFSA 2017 guidance for pesticide-containing products had no effect on general 
shape of the curve. The mean maximum absorption rate of testosterone was 0.027 
µg/cm2/h, n=8, which occurred during the first 12 hours. This was followed by a slower 
phase of testosterone absorption from 12-24 hours, with a mean rate of 0.005 µg/cm2/h. 
This time course profile is typical of finite dose applications where the solvent (or vehicle) 
used is gradually lost from the skin surface. This, in turn, can reduce the ability of the 
substance to move into and through the stratum corneum, as the dose dries onto the skin 
surface. The absorption profile was similar across the 4 different human donors used and 
accounted for 2.45% of the applied dose over 24h. This was equivalent to a mean value of 
0.246 µg testosterone/cm2, when expressed as mass per skin area for the 10 µg/cm2 dose 
application in the 8 replicates.  
OECD test guideline 428 also requires a full mass balance distribution of the applied 
material at 24 h. This includes the proportion of the dose that is left in the remaining 
epidermis and dermis following tape stripping and removal of the stratum corneum. This 
proportion of the dose applied (mean of 0.73%) is regarded as being potentially 
systemically available in a regulatory study on pesticide-containing products (EFSA, 2017).  
In the human skin part of this investigation, the mean total systemically available dose was 
3.17% of that applied to the skin. The vast majority (94.2%) of the dose was washed off 
the skin at 8 h with a further 1.34% removed from the surface in the terminal skin wash at 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
11 
 
24 h. The 15 tape strips of the stratum corneum amounted to a further 0.16% of the dose 
with 0.73% found in the remaining skin, comprising the epidermis and dermis. A mean 
total recovery of 99.0 ± 0.65% (mean ± SD) was achieved with the 8 replicates. The mass 
balance recovery of testosterone in each compartment of human skin is shown in Table 1. 
In order to see the distribution across the human skin samples, the individual data for each 
skin diffusion cell and each compartment of the investigation is shown in Table 2. 
 
4.2 Skin Penetration of Testosterone through Pig Dermatomed Skin 
The time course profile of dermal absorption of testosterone through pig skin is 
shown in Figure 2. Interestingly, the skin penetration profile in pig skin was almost identical 
to that observed in human skin in terms of lag phase and shape of the curve. As with 
human skin, the 8h interim skin surface wash had no effect on the general shape of the 
absorption curve. The clear difference from the human skin investigation was the much 
greater proportion of the applied dose of testosterone that was found in the receptor fluid 
in pig skin at 24 h. In fact, the absorption of testosterone through pig skin was between 5 
and 6 times higher than through human skin. A total of 13.1% of the dose, equivalent to 
1.33 µg testosterone/cm2, had reached the receptor fluid by 24 h. The majority of the dose 
that was found in the receptor fluid had penetrated the skin samples by 12 h, with an 
average flux over 24h of 0.055 µg/cm2/h, n=11. The time course showed the typical 
“saturation” type profile of dermal absorption with finite (low volume) doses.  
The systemically available dose that includes the dose that has penetrated to the 
epidermis and dermis, in addition to the receptor fluid was 15.8% of the dose applied to 
the skin. As with human skin, the majority of the applied dose (76.6%) could be washed off 
the skin at 8 h and a further 5.1% was removed in the terminal wash at 24 h. The 15 tape 
strips of stratum corneum amounted to a further 0.23% of the dose. Only 2.63% of the 
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testosterone dose was found in the remaining skin after tape stripping. A mean total 
recovery of 98 ± 1.6% (mean ± SD) was achieved for the 11 pig skin replicates. The mass 
balance distribution and recovery of testosterone in pig skin is shown in Table 1. The 
individual pig skin data for skin diffusion cell and each compartment of the investigation is 
shown in Table 3. 
 
5. DISCUSSION 
This investigation has compared the dermal penetration and skin distribution of an 
identical dose application of the OECD 428 reference chemical, testosterone in both 
human and pig skin. Our experiments followed the experimental design described in the in 
vitro test guideline, OECD 428, using ex vivo tissue from multiple human donors or 
animals, in the case of the pig. The actual protocol used here included an interim 
decontamination of the skin surface at 8 h, as required for the testing of crop protection 
products (EFSA, 2017). This intermediate washing step is also part of the SCCS guidance 
for dermal absorption for the evaluation of specific cosmetic products that have short 
exposure times such as hair dyes where an interim skin washing step is normally 
undertaken 30 min following skin application (SCCS, 2010).  For the various industrial 
sectors that utilise guideline OECD 428 the key aspect of the study protocol is to mimic 
real or expected exposure to the product containing the active ingredient. For pesticides 
this is the normal working day, where either the product concentrate or spray strength 
dilutions are handled by the Operator, over, for example, an 8h period. In contrast, most 
personal care products such as skin creams are “leave-on” and the duration of exposure is 
for the full 24h, with no interim skin washing step in the study design. In order to make this 
particular investigation more comprehensive we tape stripped the stratum corneum 15 
times rather the conventional 5 strips used in the EFSA guidance for dermal absorption. 
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This allowed is to profile testosterone more accurately across this outer layer of the skin in 
the two species studied. 
The primary observation of this investigation was the difference in the extent of 
dermal absorption between the two species, with human skin offering a more effective 
barrier preventing skin penetration of testosterone into the receptor fluid when compared 
with pig skin under identical experimental conditions. The magnitude of difference in 
dermal absorption was between 5 and 6-fold for this particular compound. Interestingly, 
despite the difference in the extent of absorption between species, the time course profile 
of absorption into the receptor fluid was very similar. The mass balance distribution 
provides a good explanation for the species difference in testosterone absorption. The first 
step in the dermal absorption process is the ability of the test penetrant, in its vehicle, to 
penetrate into and traverse the outer layers of the stratum corneum. Indeed, the vehicle 
itself can have a major impact on the overall skin penetration process since the first step 
involves partitioning out of the application dose and into the lipid rich outer layers of the 
stratum corneum. This vehicle effect has been shown for a number of compounds of 
differing physicochemical properties in human skin and in human volunteer studies 
(Trebilcock et al, 1994). In the case of testosterone here, the interim surface 
decontamination with soap and water at 8 h is likely to prevent the applied dose remaining 
on the surface from gaining further access to the skin after this time. In addition, the soap 
washing procedure and mechanical action of the sponges used to swab the surface, 
probably also removes a significant proportion of any testosterone in the micro-folds, 
appendages and, to a certain extent, any unabsorbed compound that is bound to the lipid-
rich areas of desquamed stratum corneum. 
The difference in the quantity of testosterone removed by the soap wash at 8 h was quite 
marked and significantly different (p<0.01) between the two species. A total of 94% of the 
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applied testosterone dose could be removed from human skin, but only 77% could be 
removed from pig skin using an identical procedure undertaken by the same Technician at 
8 h. This more effective penetration into the surface of pig skin in the first few hours 
following exposure leads to higher proportions of the testosterone dose reaching all the 
layers beyond the stratum corneum with the underlying epidermis, dermis and receptor 
fluid giving considerably higher values in pig skin compared with human skin. 
Consequently, the systemic exposure for testosterone, which, using the EFSA guidance 
description, which includes the proportion of the dose in the regions beyond the tape 
stripped stratum corneum, as “potentially absorbable” was significantly higher in pig skin at 
15.8 ± 5.91%, compared with human skin 3.17 ± 2.40% (p< 0.01).  
A key parameter in these dermal absorption and skin distribution investigations, and 
a requirement by the OECD 428 guideline, and associated industry-specific guidance, is 
an acceptable mass balance recovery of the applied dose. This “validates” the experiment 
by accounting for all the test material that was applied to the skin. In this investigation, a 
very good mass balance recovery of testosterone was achieved in both species with 99.0 
± 0.65% recovered in human skin and 98.0 ± 1.58% recovered in pig skin (values are 
mean ± SD, Table 1). This is one of the important study performance criteria in the OECD 
428 test guideline, where a mean total recovery of 95-105% of the active ingredient 
applied is required when the study forms part of a regulatory submission for a new or 
existing product as part of the human risk assessment. When there is a shortfall in total 
recovery of the applied dose, the regulatory authorities are obliged to presume that any 
missing dose may have been in one of the systemically available compartments. 
Therefore, in the spirit of conservatism, the missing fraction of the dose applied is added to 
the absorbed dose in the absence of other information. This ensures that in a human risk 
assessment that systemic exposure is not underestimated. In the case of volatile actives 
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an unoccluding carbon filter trap above the diffusion cells is sometimes used to ensure a 
good mass balance recovery. This provides the evidence on the proportion of the dose 
that was clearly unabsorbed. For drug absorption and dermal delivery investigations that 
utilise a similar in vitro protocol aligned to OECD 428, this conservative approach of 
including the “missing” dose in a mass balance as being systemically available is not 
appropriate since the objective is often to maximise the dermal absorption of the active 
from the formulated product.  
The design of the present investigation followed the guidance on the numbers of 
individual human donor skins used, and indeed, the number of different animals used 
when these studies are used for regulatory submissions to various authorities such as 
EFSA or SCCS. There is a requirement for human skin absorption studies that tissue 
should be procured from a minimum of four different human donors for each dose of an 
active ingredient. This distribution of donor and animal skin was followed in this 
investigation and ensured that any intrinsic human donor effect on dermal absorption is 
incorporated into the experimental design. In this investigation one of the human donors 
showed a slightly different skin distribution of testosterone to the other human samples in 
the group. If you examine Table 3, the diffusion cells 84 and 85 contained skin from the 
same human donor (Donor 4). Using the same washing procedure across the group, a 
similar but lower amount was removed from that donor’s skin at 8h. This only amounted to 
a few percent of the dose applied. However, the consequences were a higher amount of 
testosterone found in the skin at 24h and also higher amounts of testosterone was present 
in the receptor fluid for that particular donor.  
The overall mass balance for these two replicates was very good and close to 100%, 
which indicates that this was not a technical or analytical issue and much more likely to be 
indicative of different skin permeability properties, at least to testosterone, across the 
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population. This endorses the need to include several human donors for each dose level of 
a compound being tested using the OECD 428 in vitro dermal absorption protocol. This 
issue of variability in data from in vitro dermal absorption studies both for the distribution 
across the compartments of the study and the overall systemic exposure values across 
replicates is inherent to this study type and not often recognised when various statistical 
methods are used with such data.  In the case of animal skin studies of dermal absorption 
it is usual for the same genetic strain, age, sex and supplier of the animal skin samples to 
be used. Therefore, dermal absorption studies with animal skin are less likely to provide 
the population variability that we observe regularly with skin from different human donors, 
and indeed from different sites of the human body (WHO, 2006). The key aspect here, and 
this applies to all species, is the importance of ensuring that the skin is intact and not 
damaged by the collection, storage and dermatoming of the specimens (Heylings, 2012; 
Davies et al, 2015). This can have a much greater effect on the overall dermal absorption 
value obtained using the OECD 428 approach. 
It should be noted that the species difference in dermal absorption observed here 
relates to a single dose of one test chemical, testosterone. Furthermore, it was applied to 
the skin in an aqueous ethanol vehicle, in order to ensure that the reasonably lipophilic 
chemical was dissolved completely and homogenous in the 10µl/cm2 finite dose. It is 
therefore possible that use of a different vehicle and indeed, chemicals with different 
lipophilicities that the species difference observed here between human and pig skin may 
not be as marked under different conditions and with different chemicals. However, it is 
generally accepted that human skin has the most effective barrier to skin penetration 
across mammalian species for chemicals in general, whether they be polar or lipophilic 
(OECD 2004a; OECD 2004b; WHO, 2006).  However, in this particular investigation we 
have shown that intact human skin is a more effective barrier to the dermal absorption of 
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testosterone compared with pig skin when studied side by side and according to modern 
day in vitro dermal absorption guidance.  
Prior to the publication of the OECD test guidelines for dermal absorption in 2004, 
skin integrity investigations comparing the permeability properties of different species had 
already identified that each species had different skin permeability properties. The skin 
barrier properties to tritiated water, trans-epidermal water loss and electrical resistance 
were somewhat lower in pig skin, but certainly closer to human skin than rat skin (Davies 
et al, 2004; Heylings, 2012). Pig skin is used as surrogate for human skin for regulatory in 
vitro dermal absorption studies on personal care products (Benech-Kieffer, et al, 2000; 
Gerstel et al. 2016; SCCS, 2010). Porcine skin is also a useful model for the screening of 
different formulations containing the same active, where the objective of the investigation 
is to identify adjuvants that provide the best profile of absorption and distribution alongside 
other end points that may be a diverse as efficacy in crop protection or efficacy relating to 
drug delivery. In the case of drug research, a well-controlled in vitro pig skin protocol, 
according to the principles of OECD 428l is often used as a screen to select and optimise 
formulations ahead of a more costly human volunteer study (Herkenne et al. 2007). 
Ensuring that the skin permeability is normal in these in vitro skin studies is just as 
important in the development of topical pharmaceuticals as it is for safety studies with 
industrial chemicals.  Therefore, the OECD 428 in vitro dermal absorption method, when 
conducted correctly, has a wide range of applications in both human risk and human 
benefit.  
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Table 1: Mass Balance Distribution of Testosterone in Human and Pig Skin 
 
Test Compartment 
 
Human skin  Pig skin  
% SD % SD 
Skin wash at 8 hours 94.2  3.15 76.6  10.4 
Skin wash at 24 hours  1.34  1.26 5.13  4.45 
Stratum corneum 0.16 0.07 0.23  0.17 
Remaining epidermis 0.41 0.43 0.89  0.68 
Dermis 0.32 0.30 1.74  1.22 
Receptor fluid 2.45 2.05 13.1  4.99 
Systemically available  3.17 2.40 15.8 5.91 
Total recovered 99.0 0.65 98.0  1.58 
 
      Mean % dose applied ± Standard Deviation (SD) for each compartment   
      Testosterone dose applied to skin = 1.0 mg/ml in ethanol/water vehicle 
      Interim skin wash at 8 hours; Mass balance recovery at 24 hours    
      Human skin n=8 replicates (4 donors); Pig skin n=11 replicates (6 animals) 
      Systemically available = Receptor fluid + Remaining epidermis + Dermis 
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Table 2. Human Skin: Testosterone (1mg/mL) 
 
Test Compartment 
Percent of Dose Recovered (%) 
Cell 31 Cell 43 Cell 47 Cell 48 Cell 53 Cell 54 Cell 84 Cell 85 Mean SD 
Donor 1 Donor 1 Donor 2 Donor 2 Donor 3 Donor 3 Donor 4 Donor 4   
8h Wash Pipette <LOD 0.017¤ 0.005¤ 0.007¤ 0.030 <LOD 0.230 0.008¤ 0.049 
0.08
9 
Skin Wash @ 8h 97.3 96.9 93.0 97.4 95.6 93.9 89.8 89.5 94.2 3.19 
Total 8h Wash 97.3 96.9 93.0 97.4 95.6 93.9 90.0 89.5 94.2 3.15 
Donor Chamber 0.034 0.104 0.039 0.020¤ 0.012¤ 0.005¤ 0.225 0.216 0.082 
0.09
1 
Skin Wash @ 24h 0.437 0.924 2.17 0.556 0.647 0.360 4.05 1.58 1.34 1.26 
Tape Strips 
          
1 0.023 0.015 0.020 0.010¤ 0.031 0.005¤ 0.055 0.014 0.022 
0.01
6 
2 0.017 0.011¤ 0.024 0.011¤ 0.027 0.005¤ 0.028 <LOD 0.018 
0.00
9 
3 0.006¤ 0.010¤ 0.013 0.014 0.014 0.003¤ 0.015 <LOD 
0.011
¤ 
0.00
4 
4 0.014 0.014 0.024 0.013 0.015 0.004¤ 0.024 0.017 0.016 
0.00
6 
5 0.010¤ 0.011¤ 0.016 0.010¤ 0.012 0.008¤ 0.012 0.007¤ 
0.011
¤ 
0.00
3 
6 0.008¤ 0.005¤ 0.012 0.011¤ 0.010¤ 0.003¤ 0.017 0.007¤ 
0.009
¤ 
0.00
4 
7 0.013 0.012 0.016 0.012 0.007¤ 0.005¤ 0.012 0.006¤ 
0.010
¤ 
0.00
4 
8 0.013 0.009¤ 0.010¤ 0.007¤ 0.008¤ 0.001¤ 0.012 0.009¤ 
0.009
¤ 
0.00
4 
9 0.008¤ 0.007¤ 0.013 0.007¤ 0.002¤ 0.001¤ 0.063 0.011¤ 0.014 
0.02
0 
10 0.008¤ 0.006¤ 0.017 0.004¤ 0.006¤ 0.002¤ 0.009¤ 0.005¤ 
0.007
¤ 
0.00
4 
11 0.004¤ 0.008¤ 0.012 0.002¤ 0.003¤ 0.007¤ 0.017 0.005¤ 
0.007
¤ 
0.00
5 
12 0.001 0.005¤ 0.008¤ 0.003¤ 0.002¤ 0.0001¤ 0.014 0.010¤ 
0.005
¤ 
0.00
5 
13 0.003¤ 0.008¤ 0.017 0.007¤ 0.004¤ 0.007¤ 0.007¤ 0.023 
0.010
¤ 
0.00
7 
14 0.005¤ 0.005¤ 0.020 0.007¤ 0.013 0.003¤ 0.008¤ 0.004¤ 
0.008
¤ 
0.00
6 
15 0.009¤ 0.015 0.005¤ 0.009¤ 0.003¤ 0.005¤ 0.007¤ 0.001¤ 
0.007
¤ 
0.00
4 
Stratum Corneum                                       
(Total Tape Strips) 
0.142 0.144 0.228 0.126 0.156 0.060 0.300 0.116 0.159 
0.07
4 
Flange 0.004¤ 0.024 0.099 0.014 0.029 0.017 0.202 0.109 0.062 
0.06
9 
Dermis 0.062 0.142 0.264 0.056 0.133 0.155 0.496 0.738 0.256 
0.24
1 
Skin Membrane^ 0.065 0.166 0.363 0.070 0.162 0.172 0.698 0.847 0.318 
0.29
8 
Remaining Epidermis 0.024 0.435 1.38 0.209 0.176 0.116 0.465 0.440 0.405 
0.42
6 
Receptor Fluid 0.585 0.735 1.75 0.545 2.47 3.06 4.03 6.44 2.45 2.05 
Systemically 
available* 
0.674 1.34 3.49 0.824 2.81 3.34 5.19 7.72 3.17 2.40 
TOTAL 98.6 99.4 99.0 98.9 99.2 97.6 99.8 99.2 99.0 
0.64
5 
^Skin Membrane = Sum of Dermis and Flange (Unexposed skin) 
*Systemically available = Sum of Skin Membrane, Receptor Fluid and Remaining Epidermis (values below the double line) 
¤ = Less than LOQ (Limit of Quantification) 
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Table 3. Pig Skin: Testosterone (1mg/mL) 
 
Test 
Compartment 
Percent of Dose Recovered (%) 
Cell 43 Cell 47 Cell 48 Cell 55 Cell 62 Cell 64 Cell 67 Cell 71 Cell 85 Cell 86 Cell 98 
Mea
n SD 
Animal 
1 
Animal 
2 
Animal 
2 
Animal 
3 
Animal 
4 
Animal 
4 
Animal 
4 
Animal 
5 
Animal 
1 
Animal 
1 
Animal 
6     
8h Wash Pipette 
0.017 0.215 0.020 0.020 0.051 0.036 0.088 0.013 0.015 0.009¤ 0.173 
0.06
0 
0.07
1 
Skin Wash @ 8h 83.2 55.4 85.5 64.2 67.6 78.8 77.7 82.4 85.3 88.8 73.3 76.6 10.4 
Total 8h Wash 83.2 55.7 85.6 64.3 67.6 78.8 77.8 82.4 85.3 88.8 73.5 76.6 10.3 
Donor Chamber 
0.111 0.265 0.031 0.539 1.05 0.099 0.248 0.056 0.236 0.045 0.255 
0.26
7 
0.29
9 
Skin Wash @ 24h 1.55 11.3 0.944 8.14 12.1 1.89 9.32 1.67 2.41 0.422 6.70 5.13 4.45 
Tape Strips 
             
1 
0.021 0.017 0.040 0.006¤ 0.009¤ 0.004¤ 0.066 0.005¤ 0.008¤ 0.012¤ 0.011¤ 
0.01
8 
0.01
9 
2 
0.013 0.016 0.050 0.019 0.019 0.006¤ 0.126 0.005¤ 0.014 0.010¤ 0.008¤ 
0.02
6 
0.03
5 
3 
0.012 0.041 0.022 0.027 0.038 0.005¤ 0.022 0.001¤ 0.004¤ 0.005¤ 0.005¤ 
0.01
7 
0.01
4 
4 
0.027 0.036 0.020 0.009¤ 0.025 0.006¤ 0.019 0.006¤ 0.008¤ 0.007¤ 0.006¤ 
0.01
5 
0.01
1 
5 
0.019 0.033 0.014 0.016 0.030 0.003¤ 0.024 0.026 0.012¤ 0.006¤ 0.005¤ 
0.01
7 
0.01
0 
6 
0.008¤ 0.066 0.026 0.016 0.022 0.004¤ 0.033 0.003¤ 0.003¤ 0.003¤ 0.047 
0.02
1 
0.02
1 
7 
0.004¤ 0.009¤ 0.012 0.012 0.035 0.003¤ 0.044 
0.0009
¤ 
0.002¤ 0.004¤ 0.018 
0.01
3 
0.01
4 
8 
0.006¤ 0.021 0.011¤ 0.010¤ 0.021 0.005¤ 0.022 0.003¤ 0.003¤ 0.003¤ 0.008¤ 
0.01
0¤ 
0.00
8 
9 
0.009¤ 0.014 0.013 0.016 0.066 
0.0005
¤ 
0.030 0.001¤ 0.003¤ 0.003¤ 0.040 
0.01
8 
0.02
0 
10 
0.012 0.040 0.010¤ 0.012 0.034 0.004¤ 0.019 0.004¤ 
0.0009
¤ 
0.004¤ 0.032 
0.01
6 
0.01
4 
11 
0.009¤ 0.033 0.017 0.013 0.028 0.001¤ 0.012¤ 0.001¤ 0.003¤ 0.003¤ 0.009¤ 
0.01
2 
0.01
1 
12 
0.004¤ 0.020 0.006¤ 0.013 0.013 0.002¤ 0.068 0.004¤ 0.001¤ 0.005¤ 0.008¤ 
0.01
3 
0.01
9 
13 
0.007¤ 0.014 0.007¤ 0.006¤ 0.050 <LOD 0.006¤ 0.003¤ 
0.0004
¤ 
0.0006
¤ 
0.032 
0.01
3 
0.01
6 
14 
0.042 0.018 0.009¤ 0.013 0.011¤ 0.004¤ 0.010¤ 
0.0007
¤ 
0.003¤ 
0.0009
¤ 
0.011¤ 
0.01
1¤ 
0.01
2 
15 
0.005¤ 0.024 0.010¤ 0.011¤ 0.053 0.001¤ 0.008¤ 0.001¤ 0.001¤ 0.001¤ 0.014 
0.01
2 
0.01
5 
Stratum 
Corneum           
(Total Tape 
Strips) 
0.198 0.402 0.268 0.199 0.453 0.049 0.510 0.065 0.066 0.067 0.255 
0.23
0 
0.16
6 
Flange 
0.524 0.315 0.260 0.838 2.76 0.372 0.306 0.337 0.163 0.076 0.304 
0.56
8 
0.75 
Dermis 
0.340 1.29 0.464 3.50 0.831 1.83 1.38 0.956 0.618 0.476 1.18 1.17 
0.89
7 
Skin Membrane^ 0.864 1.60 0.724 4.34 3.59 2.20 1.68 1.29 0.781 0.552 1.48 1.74 1.22 
Remaining 
Epidermis 
0.412 1.04 0.347 2.70 0.947 1.22 0.909 0.907 0.443 0.260 0.605 
0.89
0 
0.67
9 
Receptor Fluid 10.5 25.1 11.7 17.4 11.3 14.4 7.84 10.1 11.7 8.15 16.3 13.1 4.99 
Systemically 
available* 
11.8 27.7 12.8 24.4 15.9 17.8 10.4 12.3 12.9 8.96 18.4 15.8 5.91 
TOTAL 96.8 95.3 99.6 97.6 97.1 98.6 98.3 96.5 101 98.3 99.1 98.0 1.58 
^Skin Membrane = Sum of Flange and Dermis 
*Systemically available = Sum of Skin Membrane, Receptor Fluid and Remaining Epidermis (values below the double line) 
¤ = Less than LOQ (Limit of Quantification) 
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Highlights 
 Dermal absorption of testosterone has been assessed using OECD 428 test 
guideline 
 Mass balance distribution of testosterone was compared in both human and 
pig skin 
 Absorption profiles were similar but pig skin was more permeable to 
testosterone 
 Resected skin is now a widely accepted model to predict systemic exposure in 
man  
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